Your sibling is in a liver unit with hepatitis B that suddenly tipped into acute-on-chronic liver failure. A relative overseas says thymosin alpha-1 “improves survival in HBV liver failure” and forwards a paper screenshot plus a research-catalog link. The family wants to know what the hospital study actually measured–and what it did not.
There is an open-label randomized trial in that setting. It reported better 90-day transplant-free survival when thymosin alpha-1 was added to standard medical therapy, with accompanying immune-cell shifts. It was not blinded, and it did not test a catalog vial sold for everyday immune support.
What the HBV-ACLF randomized trial found
Li and colleagues reported the study in Immunopharmacology and Immunotoxicology in 2026. Seventy-three adults with hepatitis B-related acute-on-chronic liver failure were assigned to standard medical therapy alone (38 people) or standard care plus thymosin alpha-1 (35 people). The trial is registered as NCT03082885.
Thymosin alpha-1 treatment was linked to higher 90-day transplant-free survival. Survivors at day 90 tended to start with more effector T cells, fewer regulatory T cells, and a different cytokine pattern than people who died or needed transplant. Over time, survivors’ inflammatory markers eased, while non-survivors drifted toward a worsening inflammatory storm. In the thymosin arm, regulatory T-cell frequencies fell at weeks four to eight, and late hyperinflammation looked more contained without wiping out early immune activation–the authors’ framing of “rebalancing” rather than blanketing the immune system.
Because the trial was open-label, bedside teams and patients knew the assignment. That design can inflate perceived benefit even when lab measures move. The paper still matters as a hospital-file data point; it is not a consumer protocol.
Where this hospital file sits among earlier thymosin stories
Earlier Everyday Brief thymosin alpha-1 pieces tracked Zadaxin overseas licensing, the TESTS sepsis phase 3 with no day-28 survival edge, Maio’s 2010 melanoma combination results, and Shehadeh’s open-label COVID ward pilot with a CD4 lab bump. Severe HBV acute-on-chronic liver failure is a different bedside decision. Those prior sources also did not study a research-shelf peptide sold for day-to-day immune support.
MedlinePlus and NIDDK hepatitis B pages still emphasize vaccination, monitoring, antivirals when indicated, and urgent care for liver-failure warning signs. A forwarded screenshot is not a transplant-team order set.
What to ask the liver team
Ask which antivirals, infection precautions, transplant evaluation steps, and monitoring labs are already in place. If someone mentions thymosin alpha-1, clarify whether they mean this open-label HBV-ACLF randomization, a medicine licensed outside the U.S., or a laboratory catalog SKU–and whether that hospital is running a related study.
A survival curve can look decisive in a family chat. In this file it is one open-label randomized signal in a high-risk hospital population–not proof that a catalog peptide changes home care.
Not medical advice.
Sources
- Li J et al. Thymosin alpha-1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance. Immunopharmacol Immunotoxicol, 2026 (PubMed)
- ClinicalTrials.gov: NCT03082885
- MedlinePlus: Hepatitis B
- NIDDK: Hepatitis B
Related reading
- Hospital COVID and thymosin alpha-1: what a small pilot found
- TESTS phase 3: no 28-day survival benefit in sepsis
- Zadaxin overseas history versus U.S. catalog screenshots
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-15 PT. Not medical advice.